The overarching goal of Dr. Kretzler’s research team is to define renal failure in mechanistic terms and use this knowledge for targeted therapeutic interventions. To reach this goal he has developed a translational research pipeline centered on integrated systems biology analysis of renal disease.He leads the Nephrotic Syndrome Research Network (Neptune) in the Rare Disease Clinical Research Network II, the Coordinating center of the CureGN research network, is the Director of the Applied Systems Biology Core at the Michigan Kidney center and in the NIH Acceleration of Medicine (AMP) program in autoimmunity.He has 20 years of experience in integration of bioinformatics, molecular and clinical approaches in more than 230 papers. He and his team perform interdisciplinary data integration of large-scale data sets in international multi-disciplinary research networks in the US, Europe and China. These studies enable precision medicine genes to disease manifestation in patients using carefully monitored environmental exposures, genetic predispositions, epigenetic markers, transcriptional networks, proteomic profiles, metabolic fingerprints, digital histological biopsy archive and prospective clinical disease characterization. The molecular mechanism identified in these studies have result in new disease predictors and the first successful phase II trial of a novel therapy (Jak2 inhibition, http://www.uofmhealth.org/news/archive/201506/fast-tracking-precision-medicine-science-guides-re-aiming) in diabetic kidney disease in two decades.